title: Ten-year survival of curability B gastric cancer patients treated by tegafur-uracil as postoperative adjuvant chemotherapy in a common public hospital: univariate and multivariate analyses.
abstract: OBJECTIVE
  The prognosis of gastric cancer patients undergoing curability B surgery was retrospectively examined to determine the effectiveness of the administration of oral anti-cancer drugs as postoperative adjuvant chemotherapy.
  
  
  METHODS
  This study was based on the outcomes of 86 potentially curative patients who had undergone curability B resection of gastric cancer with or without the subsequent administration of oral 5-fluorouracil analogue. There were 21 patients who underwent surgery alone with no oral anti-cancer agents (group A) and 65 patients who were treated postoperatively, mainly with UFT (Tegafur and uracil; group B). This study compared the ten-year survival times of these two groups using univariate and multivariate analyses.
  
  
  RESULTS
  The amount of UFT in group B was 354.2 +/- 122.0 mg and the administration period was 11.7 +/- 7.2 months. The backgrounds showed significantly more older patients in group A compared than group B (P = 0.0002). A univariate analysis showed the ten-year survival rate in group B to be higher than group A (P = 0.0079). A multivariate analysis showed that the postoperative administration of UFT was an independent factor associated with prolongation of survival times as well as the extent of lymph nodes metastasis and pathological stage (P = 0.0096).
  
  
  CONCLUSIONS
  This study provided conventional evidence that postoperative administration of oral 5-fluorouracil analogue is associated with better long-term prognoses in patients undergoing curability B resection for gastric carcinoma.
authors.affiliation: Department of surgery, Fukuoka City Hospital 13-1 Yoshizuka-honmachi Hakata-ku, Fukuoka city, 812-0046 Japan. okuyama929@yahoo.co.jp
authors.forename: Toshiro
authors.initials: T
authors.lastname: Okuyama
authors.forename: Takahiro
authors.initials: T
authors.lastname: Higashi
authors.forename: Ai
authors.initials: A
authors.lastname: Edagawa
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Nagata
authors.forename: Kenkichi
authors.initials: K
authors.lastname: Hashimoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Saeki
authors.forename: Eiji
authors.initials: E
authors.lastname: Oki
authors.forename: Hideaki
authors.initials: H
authors.lastname: Uchiyama
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Kawanaka
authors.forename: Masaru
authors.initials: M
authors.lastname: Morita
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tateishi
authors.forename: Daisuke
authors.initials: D
authors.lastname: Korenaga
authors.forename: Hidemichi
authors.initials: H
authors.lastname: Yaita
authors.forename: Kenji
authors.initials: K
authors.lastname: Takenaka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D059186:Chemoradiotherapy, Adjuvant; D013505:Digestive System Surgical Procedures; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011182:Postoperative Care; D011379:Prognosis; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D013997:Time Factors; D014498:Uracil / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D005641:Tegafur; D014498:Uracil